Cephalon CEO now on indefinite medical leave

Cephalon CEO Frank Baldino won't be returning from medical leave as quickly as the developer once believed. Without saying what Baldino is suffering from, the biotech says that the medical leave, once estimated at four months, will now be for an indefinite period of time. COO J. Kevin Buchi will continue to handle the day-to-day duties at the company. Story

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.